COMPANY PROFILE

Polyplus-transfection

Explore full profile

Provides specialised reagents, kits and services for nucleic-acid delivery in gene and cell therapy production

Illkirch, FranceFounded 2001Biotech & Life Sciences

Valuation $2.5–5B Last recorded · 2023

Revenue $50–100M Latest reported FY

Headcount 100–500 Current team size

Total funding $0–10M Disclosed equity funding

Unlock exact values

About Polyplus-transfection

Polyplus is a biotechnology company specializing in the development, marketing, and sale of advanced solutions for the delivery of nucleic acids. The company serves clients in the research, bioproduction, and therapeutic sectors, providing essential tools for gene and cell therapy production. Operating in the global biotechnology market, Polyplus offers a range of products including transfection reagents, kits, and support services. In 2022, the company expanded its portfolio to include custom plasmid vector design, aiming to optimize process economics while adhering to stringent scientific and regulatory standards. Polyplus generates revenue through the sale of its innovative products and services, catering to both academic and commercial clients engaged in proof-of-concept studies, preclinical studies, and clinical trials. The company is committed to reliability, safety, and cost-effectiveness in nucleic acid-based therapies.

MoreLess Source: Dealroom company data

At a glance

Founded: 2001
Headquarters: Illkirch, France
Sector: Biotech & Life Sciences
Power Law: Unicorn$1–10B valuation tierColt$25–100M revenue

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

CFCIC Finance
CECrédit Mutuel Equity

Series B and later1 investor entered at this stage

WPWarburg Pincus

Talent

Book a demo to see the people

Team profiled 14 named & role-tagged

Founders /100 quality score

Key operators 3 quality /100

Potential founders likely future founders

Startup mafia alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country

Workforce by country

3 countries with
team presence

🇫🇷 France92.2%

🇨🇳 China3.1%

🇺🇸 United States3.1%

3 countries shown

Patents

Estimated portfolio value

$18M

19 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Polyplus-transfection on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Polyplus-transfection on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles